Chronic treatment of old mice with AICAR reverses age-related changes in exercise performance and skeletal muscle gene expression.

ABSTRACT: Sarcopenia refers to the decline in muscle mass and function that occurs with advancing age. It is driven by alterations in multiple cellular processes. AMP-activated protein kinase (AMPK) is a cellular energy sensor that opposes many age-related changes, making it an attractive target for the treatment of sarcopenia. This study aimed to test the effect of chronic treatment of old mice with the AMPK-activating prodrug, AICAR, on treadmill running capacity and muscle mass, force production, gene expression, and intracellular markers relevant to sarcopenia. Old (23 months) mice were tested for treadmill running capacity, then randomly assigned to receive daily treatment with AICAR (OA; 300 to 500 mg/kg, delivered via subcutaneous injection) or an equivalent volume of saline vehicle (OS) for

SUBMITTER: Wilcox SH 

PROVIDER: S-EPMC11886611 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature